Generated by AI
Vivos Therapeutics, Inc. is a medical technology company that concentrates on addressing sleep apnea through innovative treatment solutions. Primarily known for its proprietary systems and devices, the company offers a non-surgical approach designed to improve airway function and alleviate symptoms for patients suffering from obstructive sleep apnea (OSA), a common and often undiagnosed condition linked to various health issues. Operating at the intersection of medical devices and dental care, Vivos provides its solutions primarily to healthcare professionals, enabling them with tools and training necessary to effectively manage and treat sleep disorders. This focus on a non-invasive methodology has positioned Vivos as a notable player in the sleep disorder treatment market. Its approach not only aims to provide relief for individuals but also reduces dependency on traditional continuous positive airway pressure (CPAP) machines. Vivos Therapeutics plays a significant role in enhancing patient care within the healthcare sector by bridging the gap between dentistry and medicine, helping to raise awareness and offer alternative treatments for sleep-related breathing disorders.
Website7921 Southpark Plaza
Littleton, CO, 80120
United States
The latest articles about VVOS.
Vivos Therapeutics (VVOS) delivered earnings and revenue surprises of +76.67% and +17.15%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
This release removes the mention of Cleveland Clinic Weston.Partnership unites the ReBalU Protocol, Vivos's sleep platform, and a new test for cells primed for chronic disease, reaching nearly 500,000 chronic disease patientsVERO BEACH, FL / ACCESS Newswire / October 29, 2026 / SOD Sciences, Inc.
LITTLETON, Colo., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (Nasdaq: VVOS), a medical device and healthcare services company focused on developing and commercializing diagnostic and treatment methods for patients with obstructive sleep apnea (“OSA”) and other breathing and sleep-related health conditions, today announced receipt of a letter from the Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) on October 20, 2026
Summary of Nov 17's posts. Generated by AI.
Summary of Oct 21's posts. Generated by AI.
Summary of Oct 21's posts. Generated by AI.
Investors talking about VVOS also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.